Business
CEO Appointment
CEO Appointment.
About this update from Proteome Sciences Plc
[{"type":"text","content":"\n \nRNS Number : 5310Y Proteome Sciences PLC 18 May 2016 \n\n \n \n \n \nPRESS RELEASE\n \nCEO Appointment \n18 May 2016\nAgainst the buoyant background and trajectory of the PS Biomarker Services business it is now appropriate to expand the executive team with a senior figure strongly connected to the pharmaceutical industry and to split the role of Executive Chairman.\nProteome Sciences is delighted to announce that Jeremy Haigh will be joining the board as CEO in June (subject to regulatory approval). He is a strong advocate of Precision Medicine and will bring numerous industry contacts and considerable commercial experience to the role. \nJeremy is an established leader in the biopharmaceutical sector with 30 years in clinical and operational research and development, principally at Merck and Amgen where most recently he was European Chief Operating Officer, R&D. \nHis basic training was in neuropharmacology and he has been significantly involved in healthcare policy and government affairs in the UK and Europe having served on the board of the BioIndustry Association (BIA), the European Federation of Pharmaceutical Industries (EFPIA) Research Directors Group, and the Association of the British Pharmaceutical Industry Innovation Board (ABPI). He is currently the Chairman of Cogent Skills Limited and a member of Imperial College Health Partners Advisory Council.\nWith the news of his appointment, Jeremy Haigh commented, \n\"I am delighted to be joining Proteome Sciences at a time of tremendous opportunity. The challenge of developing more precise therapeutics coupled with growing patient expectations is creating a highly receptive environment for our enabling technologies and I look forward to working with the board and the entire team to realise this potential.\"\nChristopher Pearce added,\n\"As Chairman, I look forward to working closely with Jeremy and the executive team to help them exploit the considerable commercial opportunities arising in Precision Medicine from the outstanding proteomics platform Proteome Sciences has established to deliver truly personalised medicine.\"\n \nENDS\n \nFor further information please contact:\n \n\n\n\n\n\nProteome Sciences plc\n\n\n \n\n\n\n\nChristopher Pearce, Executive Chairman\n\n\n \n\n\n\n\nDr. Ian Pike, Chief Operating...